Category: Latest News

Reviewed by MSAA Chief Medical …

Challenges presented by the CO …

On April 30, 2020, Banner Life Sciences LLC (Banner), a privately held specialty pharmaceutical company, announced the United States Food and Drug Administration (FDA) approval of Bafiertam™ (monomethyl fumarate) delayed-release oral capsules to treat relapsing forms of multiple sclerosis (MS). This approval includes the treatment of clinically isolated syndrome (CIS), relapsing-remitting MS (RRMS), and active secondary-progressive MS (SPMS). Banner has not yet announced when the medication will be available to the MS community.

Reviewed by MSAA Chief Medical …

The “coronavirus disease 2019” (COVID-19) is a potentially serious respiratory disease that was first reported in December 2019 in China. As of early March 2020, the illness had made its way to almost 70 locations, including the United States, and has affected more than 90,000 individuals worldwide. Please be aware that these figures are expected to increase on a weekly or even a daily basis.

The Multiple Sclerosis Associa …

The Multiple Sclerosis Associa …

To live with multiple sclerosis (MS) is to cope with the challenges it presents and to look forward to the promise of ongoing progress in understanding and managing the condition. This edition of “What’s New in MS Research” reflects that mix of obstacles and opportunities.

The Multiple Sclerosis Associa …

The Multiple Sclerosis Associa …